Monday, March 30

UCLA appoints associate vice chancellor for intellectual property, research

UCLA officials appointed a lawyer as the associate vice chancellor for intellectual property and industry sponsored research and leader of an entrepreneurship advising board Tuesday. Amir Naiberg has been leading the Office of Intellectual Property and Industry Sponsored Research and has been the chief executive officer of Westwood Technology Transfer since Aug. Read more...

Photo: Amir Naiberg was appointed as the UCLA associate vice chancellor for intellectual property and industry sponsored research Tuesday. (Courtesy of UCLA Newsroom)


Officials appoint permanent dean of UCLA medical school

Officials appointed professor and interim dean as permanent dean of the UCLA David Geffen School of Medicine effective July 1. School officials chose Kelsey Martin after a national search, said Executive Vice Chancellor and Provost Scott Waugh in an email announcement. Read more...

Photo: Dr. Kelsey Martin, who previously served as interim dean of the David Geffen School of Medicine, was appointed permanent dean Friday. (UCLA Media Relations)


UCLA brings children together at annual pediatric craniofacial picnic

For one day each year, kids with craniofacial anomalies spend time with each other and their families at UCLA’s Sunset Canyon Recreation Center lawn. At the annual UCLA Pediatric Craniofacial Program picnic, held Aug. Read more...

Photo: Children played at the UCLA Sunset Canyon Recreation Center during a picnic hosted by the UCLA Pediatric Craniofacial Program clinic, which helps treat cleft lips and palates. (Courtesy of Justine Lee)





UCLA researchers develop new immunotherapy for advanced brain cancer

UCLA researchers have developed a new combination immunotherapy to treat advanced brain cancer. The combination treatment works by preventing brain cancer cells from shielding themselves from a patient’s own immune responses. Read more...

Photo: Robert M. Prins, leader of the cancer research team that discovered effective immunity to glioblastoma requires a robust killer T cell response in order to attenuate immune cells within the tumor.(Courtesy of Robert Prins)



1 200 201 202 203 204 341